A Phase 3 International, Multicenter, Open-label Study to Evaluate the Safety and Immunogenicity of 9vHPV Vaccine Administered as 2-dose Regimen with Extended Dosing Intervals in 9- to 14-Year Old Boys and Girls Compared with a Standard 3-dose Regimen in 16- to 26-Year Old Women

11, 16, 18, 31, 33, 45, 52, and 58, Prevention of persistent anogenital HPV infection and disease caused by HPV Types 6

Geometric Mean Titers of Anti-Human Papilloma Virus Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 as Measured by Competitive Luminex Immunoassay at 4 Weeks Post Last Vaccination, Percentage of Participants With at Least 1 Solicited Injection-site Adverse Event, Percentage of Participants With at Least 1 Systemic Adverse Event, Percentage of Participants With at Least 1 Serious Vaccine-Related Adverse Event

Percentage of Participants (Cohorts 1 to 5) Who Are Seropositive for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at 4 Weeks Post Last Vaccination, Geometric Mean Titers (Cohorts 1 to 5) of Anti-HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at 12 Months Post Last Vaccination, Percentage of Participants (Cohorts 1 to 5) Who Are Seropositive for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at 12 Months Post Last Vaccination, Geometric Mean Titers (Cohorts 1 to 5) of Anti-HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at 24 Months Post Last Vaccination, Percentage of Participants (Cohorts 1 to 5) Who Are Seropositive for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at 24 Months Post Last Vaccination, Geometric Mean Titers (Cohorts 1 to 5) of Anti-HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at 36 Months Post Last Vaccination, Percentage of Participants (Cohorts 1 to 5) Who Are Seropositive for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at 36 Months Post Last Vaccination

No related papers found yet.

Poland